Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Chidamide in R/R ENKTCL
NCT03820596Phase 2Completed
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL). Started Mar 2019; status: completed.
02
Drugs
sintilimabtucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03820596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820596.